Evidence map›Paper›PMID 37314349›Full record

ArticleAntimicrobial agents and chemotherapy2023

Antiplasmodial Activity Evaluation of a Bestatin-Related Aminopeptidase Inhibitor, Phebestin.

Nanang R Ariefta, Baldorj Pagmadulam, Masaki Hatano, Noriko Ikeda, Kunio Isshiki, Kazuaki Matoba, Masayuki Igarashi, Coh-Ichi Nihei, Yoshifumi Nishikawa

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. In Silico Screening ofBiologics : targets & therapy · 2025
    Article
  3. Ubenimex combined with Albendazole for the treatment ofFrontiers in veterinary science · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Nanang R ArieftaNational Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Japan.ORCID 0000-0002-3012-6005
Baldorj PagmadulamNational Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Japan.
Masaki HatanoInstitute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Noriko IkedaInstitute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Kunio IsshikiInstitute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Kazuaki MatobaInstitute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Masayuki IgarashiInstitute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Coh-Ichi NiheiInstitute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Yoshifumi NishikawaNational Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Japan.ORCID 0000-0001-5005-6377
Microbial Chemistry Research Foundation · JPObihiro University of Agriculture and Veterinary Medicine · JPMongolian Academy of Sciences · MN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing burden and spread of resistant malaria parasites remains an immense burden to public health. These factors have driven the demand to search for a new therapeutic agent. From our screening, phebestin stood out with nanomolar efficacy against Plasmodium falciparum 3D7. Phebestin was initially identified as an aminopeptidase N inhibitor. Phebestin inhibited the

Indexed as

AntimalarialsMalariaMalaria, FalciparumAminopeptidasesAnimalsChloroquineHumansLeucineMiceOligopeptidesParasitemiaPlasmodium bergheiPlasmodium falciparumAminopeptidasesAntimalarialsChloroquineLeucineOligopeptidesphebestinubenimexaminopeptidase inhibitorantiplasmodialphebestinPlasmodium bergheiPlasmodium falciparumPlasmodium yoelii

Identifiers

PMID37314349
PMCPMC10353437
OpenAlexW4380577076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.